CNS Pharmaceuticals, Inc. Payments for Repurchase of Initial Public Offering
CNS Pharmaceuticals, Inc. (CNSP) reported Payments for Repurchase of Initial Public Offering of $64.08 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRepurchaseOfInitialPublicOffering · last filed 2026-03-31
- CNS Pharmaceuticals, Inc. payments for repurchase of initial public offering for the quarter ending 2025-12-31 was $64.08K, a 540.82% increase year-over-year.
- CNS Pharmaceuticals, Inc. payments for repurchase of initial public offering for the quarter ending 2024-12-31 was $10.00K, a 95.07% decline year-over-year.
- CNS Pharmaceuticals, Inc. payments for repurchase of initial public offering for the quarter ending 2024-09-30 was $40.00K.
- CNS Pharmaceuticals, Inc. payments for repurchase of initial public offering for the quarter ending 2023-12-31 was $202.86K.
- CNS Pharmaceuticals, Inc. payments for repurchase of initial public offering for fiscal 2025 was $64.08K, a 4.00% decline from fiscal 2024.
- CNS Pharmaceuticals, Inc. payments for repurchase of initial public offering for fiscal 2024 was $66.75K, a 67.10% decline from fiscal 2023.
- CNS Pharmaceuticals, Inc. payments for repurchase of initial public offering for fiscal 2023 was $202.86K.
- CNS Pharmaceuticals, Inc. payments for repurchase of initial public offering for fiscal 2022 was $0.00.
| Period end | Payments for Repurchase of Initial Public Offering 3 month | Payments for Repurchase of Initial Public Offering 6 month | Payments for Repurchase of Initial Public Offering 9 month | Payments for Repurchase of Initial Public Offering 12 month |
|---|---|---|---|---|
| 2025-12-31 | $64.08K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $64.08K 10-K · filed 2026-03-31 | ||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-14 | |||
| 2024-12-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $50.00K derived: sum of 2 quarters · filed 2026-03-31 | $66.75K 10-K · filed 2026-03-31 | |
| 2024-09-30 | $40.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $56.75K 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | $16.75K 10-Q · filed 2025-08-14 | |||
| 2023-12-31 | $202.86K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $202.86K derived: sum of 2 quarters · filed 2025-03-31 | $202.86K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-14 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |